跳至主要内容
临床试验/NL-OMON52852
NL-OMON52852尚未招募3 期

A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety,and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis - PURSUIT 2

Janssen-Cilag0 个研究点目标入组 4 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
Janssen-Cilag
入组人数
4

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 17(—)

入选标准

  • -Must either be currently receiving treatment with, or have a history of having
  • failed to respond to, or have a medical contraindication to at least 1 of the
  • following therapies: oral or intravenous corticosteroids, 6- mercaptopurine,
  • methotrexate or azathioprine OR must either have or have had a history of
  • corticosteroid dependency (that is an inability to successfully taper
  • corticosteroids without a return of the symptoms of ulcerative colitis [UC]) OR
  • required more than 3 courses of corticosteroids in the past year
  • - Moderately to severely active UC (as defined by baseline Mayo score of 6
  • through 12 [endoscopy {sigmoidoscopy or colonoscopy} sub score assigned by
  • local endoscopist], inclusive), including a (sigmoidoscopy or colonoscopy) sub
  • score greater than or equal to (>=2)
  • - If receiving parenteral or enteral nutrition, must have been on a stable
  • regimen for at least 2 weeks prior to the first administration of study
  • intervention at Week 0
  • - No history of latent or active tuberculosis prior to screening
  • - Acceptable evidence of immunity to measles, mumps, rubella, and varicella

排除标准

  • - History of liver or renal insufficiency; significant cardiac, vascular,
  • pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic,
  • psychiatric (including suicidality), or metabolic disturbances
  • - History of malignancy or macrophage activation syndrome (MAS) or
  • hemophagocytic lymphohistiocytosis (HLH)
  • - Have UC limited to the rectum only or to <20 percent (%) of the colon
  • - Presence of a stoma
  • - Presence or history of a fistula
  • - Contraindications to the use of golimumab or infliximab or anti-tumor
  • necrosis factor (TNF-alpha) therapy per local prescribing information

研究者

发起方
Janssen-Cilag

相似试验